ArticleClinical and translational science2026
Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug-Drug Interactions After Posaconazole Discontinuation.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug-Drug Interactions After Posaconazole Discontinuation.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Posaconazole is a broad-spectrum triazole antifungal agent indicated for the prophylaxis and treatment of invasive fungal infections. Posaconazole pharmacokinetics and drug-drug interactions (DDIs), due to cytochrome P450 3A4 (CYP3A4) inhibition, have been previously characterized. This pharmacokinetic simulation study assessed whether the known weight-dependent effects on posaconazole pharmacokinetics could prolong the risk of CYP3A4-mediated DDIs following posaconazole discontinuation in persons with obesity. A population pharmacokinetic model developed from 1092 individuals showed 25% lower average steady-state posaconazole concentrations in individuals with body weight 120 kg versus 70 kg. Steady-state posaconazole concentration-time profiles following administrations of therapeutic doses and upon discontinuation of dosing were simulated across a range of body weights (70-180 kg). Simulated concentration-time profiles were evaluated against the in vitro CYP3A4 inhibition constant (K
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.